- Home
- CLVT vs MRUS Comparison
CLVT vs MRUS Comparison
Compare CLVT & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLVT
- MRUS
- Stock Information
- Founded
- CLVT 2016
- MRUS 2003
- Country
- CLVT United Kingdom
- MRUS Netherlands
- Employees
- CLVT N/A
- MRUS N/A
- Industry
- CLVT EDP Services
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- CLVT Technology
- MRUS Health Care
- Exchange
- CLVT Nasdaq
- MRUS Nasdaq
- Market Cap
- CLVT 2.8B
- MRUS 2.7B
- IPO Year
- CLVT N/A
- MRUS 2016
- Fundamental
- Price
- CLVT $4.32
- MRUS $41.39
- Analyst Decision
- CLVT Hold
- MRUS Strong Buy
- Analyst Count
- CLVT 4
- MRUS 14
- Target Price
- CLVT $5.83
- MRUS $87.00
- AVG Volume (30 Days)
- CLVT 5.5M
- MRUS 786.0K
- Earning Date
- CLVT 04-29-2025
- MRUS 05-07-2025
- Dividend Yield
- CLVT N/A
- MRUS N/A
- EPS Growth
- CLVT N/A
- MRUS N/A
- EPS
- CLVT N/A
- MRUS N/A
- Revenue
- CLVT $2,529,200,000.00
- MRUS $54,732,000.00
- Revenue This Year
- CLVT N/A
- MRUS $26.81
- Revenue Next Year
- CLVT $0.46
- MRUS $23.85
- P/E Ratio
- CLVT N/A
- MRUS N/A
- Revenue Growth
- CLVT N/A
- MRUS N/A
- 52 Week Low
- CLVT $3.04
- MRUS $33.19
- 52 Week High
- CLVT $7.30
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- CLVT 62.57
- MRUS 50.29
- Support Level
- CLVT $4.13
- MRUS $37.92
- Resistance Level
- CLVT $4.41
- MRUS $46.36
- Average True Range (ATR)
- CLVT 0.19
- MRUS 2.44
- MACD
- CLVT 0.09
- MRUS -0.13
- Stochastic Oscillator
- CLVT 80.71
- MRUS 60.55
About CLVT Clarivate Plc
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas while Europe, Middle East, and Africa account for around a quarter.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.